VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 12,400 shares, a drop of 63.4% from the February 29th total of 33,900 shares. Based on an average trading volume of 117,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are short sold.

Institutional Investors Weigh In On VYNE Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP grew its stake in VYNE Therapeutics by 9.3% in the first quarter. Susquehanna International Group LLP now owns 18,012 shares of the company’s stock valued at $55,000 after acquiring an additional 1,528 shares during the period. Vanguard Group Inc. lifted its holdings in VYNE Therapeutics by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 49,582 shares of the company’s stock worth $116,000 after acquiring an additional 4,687 shares during the period. HRT Financial LP bought a new stake in VYNE Therapeutics during the first quarter worth $31,000. Renaissance Technologies LLC lifted its holdings in VYNE Therapeutics by 41.0% during the second quarter. Renaissance Technologies LLC now owns 36,076 shares of the company’s stock worth $148,000 after acquiring an additional 10,495 shares during the period. Finally, Northern Trust Corp bought a new stake in VYNE Therapeutics during the fourth quarter worth $86,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Thursday, February 29th.

VYNE Therapeutics Price Performance

NASDAQ VYNE opened at $2.96 on Thursday. The business has a 50 day simple moving average of $2.13 and a 200 day simple moving average of $2.76. VYNE Therapeutics has a one year low of $1.67 and a one year high of $8.73. The stock has a market capitalization of $41.74 million, a P/E ratio of -0.42 and a beta of 1.18.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.30. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.15 million. Equities analysts expect that VYNE Therapeutics will post -1 earnings per share for the current year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.